Last edition
News about "Small Lymphocytic Lymphoma"
Lilly's Jaypirca Cuts Disease Progression Risk by 45 Percent in CLL/SLL
Lilly’s Jaypirca (pirtobrutinib) reduced the risk of disease progression or death by 45 percent when combined with a time-limited venetoclax regimen in previously treated CLL/SLL patients, according to phase 3 BRUIN CLL-322 trial results.
Small Lymphocytic Lymphoma | 15/06/2026 | By News Bureau
FDA clears 14-month, chemotherapy-free combination for first-line treatment of chronic lymphocytic leukaemia and small lymphocytic lymphoma, backed by positive Phase III AMPLIFY trial data.
Small Lymphocytic Lymphoma | 23/02/2026 | By News Bureau | 235
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy